LIVIVO - Search results -

Search results

Result 1 - 10 of total 49

Search options

Article ; Online: Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.

Weisel, Katja / Krishnan, Amrita / Schecter, Jordan M / Vogel, Martin / Jackson, Carolyn C / Deraedt, William / Yeh, Tzu-Min / Banerjee, Arnob / Yalniz, Fevzi / Nesheiwat, Tonia / Van Sanden, Suzy / Diels, Joris / Valluri, Satish / Usmani, Saad Z / Berdeja, Jesus G / Jagannath, Sundar / Martin, Tom

Clinical lymphoma, myeloma & leukemia

2022 Volume 22, Issue 9, Page(s) 690–701

Abstract: Introduction: This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel; CARTITUDE-1), a chimeric antigen receptor (CAR)-T-cell therapy, versus 3 non-CAR-T therapies (belantamab mafodotin [DREAMM-2], selinexor plus ... ...

Abstract	Introduction: This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel; CARTITUDE-1), a chimeric antigen receptor (CAR)-T-cell therapy, versus 3 non-CAR-T therapies (belantamab mafodotin [DREAMM-2], selinexor plus dexamethasone [STORM Part 2], and melphalan flufenamide plus dexamethasone [HORIZON]), each with distinct mechanisms of action, for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were triple-class exposed to an immunomodulatory drug, proteasome inhibitor, and an anti-CD38 monoclonal antibody. Patients and methods: Pairwise matching-adjusted indirect treatment comparisons (MAICs) were conducted using patient-level data for cilta-cel from CARTITUDE-1 and summary level data for each comparator (2.5 mg/kg cohort in DREAMM-2, modified intention-to-treat population in STORM Part 2, and triple-class refractory patients in HORIZON). Treated patients from CARTITUDE-1 who satisfied the eligibility of the comparator trial were included. MAICs adjusted for imbalances in important prognostic factors between CARTITUDE-1 and the comparator populations. Comparative efficacy of cilta-cel versus each therapy was estimated for overall response rate, complete response or better rate, progression-free survival, and overall survival. Results: After adjustment, patients treated with cilta-cel demonstrated at least a 3.1-fold and at least a 10.3-fold increase in the likelihood of achieving an overall response or complete response or better, respectively, at least a 74% reduction in the risk of disease progression or death, and at least a 47% reduction in the risk of death. These results were statistically significant. Conclusion: Cilta-cel showed improved efficacy over each comparator for all outcomes, demonstrating its potential as an efficacious treatment for patients with triple-class exposed RRMM.
MeSH term(s)	Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Dexamethasone/pharmacology ; Dexamethasone/therapeutic use ; Humans ; Hydrazines ; Melphalan/pharmacology ; Melphalan/therapeutic use ; Multiple Myeloma/drug therapy ; Multiple Myeloma/etiology ; Triazoles
Chemical Substances	Antibodies, Monoclonal, Humanized ; Hydrazines ; Triazoles ; selinexor (31TZ62FO8F) ; Dexamethasone (7S5I7G3JQL) ; belantamab mafodotin (DB1041CXDG) ; Melphalan (Q41OR9510P)
Language	English
Publishing date	2022-05-23
Publishing country	United States
Document type	Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2540992-X
ISSN	2152-2669 ; 2152-2650
ISSN (online)	2152-2669
ISSN	2152-2650
DOI	10.1016/j.clml.2022.04.025
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5903: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Heart-Lung Transplant via an Eighth-Time Sternotomy.

Riggs, Kyle W / Chin, Clifford W / Bryant, Roosevelt / Zafar, Farhan / Chin, Clifford / Schecter, Marc G / Morales, David L S

World journal for pediatric & congenital heart surgery

2019 Volume 12, Issue 1, Page(s) 136–138

Abstract: We report a combined heart-lung transplantation following seven prior sternotomies in a patient born with a transitional atrioventricular septal defect. Previous surgeries to repair and replace the mitral valve led to pulmonary vein stenosis and ... ...

Abstract	We report a combined heart-lung transplantation following seven prior sternotomies in a patient born with a transitional atrioventricular septal defect. Previous surgeries to repair and replace the mitral valve led to pulmonary vein stenosis and pulmonary vascular disease. Eighth-time sternotomy and significant vascular adhesions led to a prolonged operation and to placing the heart-lung block anterior to the phrenic nerves. Despite this, the patient was ready for discharge after two weeks and continues to do well over nine months later. As more patients survive multiple cardiac palliations with some developing pulmonary vascular disease, heart-lung transplantation may become relevant again.
MeSH term(s)	Adolescent ; Echocardiography ; Heart Septal Defects/diagnosis ; Heart Septal Defects/surgery ; Heart-Lung Transplantation/methods ; Humans ; Male ; Sternotomy/methods ; Tomography, X-Ray Computed
Language	English
Publishing date	2019-04-24
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2550261-X
ISSN	2150-136X ; 2150-1351
ISSN (online)	2150-136X
ISSN	2150-1351
DOI	10.1177/2150135118815876
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Adjusted comparison of outcomes between patients from CARTITUDE-1

Haematologica

2023 Volume 108, Issue 8, Page(s) 2192–2204

Abstract: Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy studied in patients with multiple myeloma exposed to three classes of treatment in the single-arm CARTITUDE-1 study. To assess the effectiveness of cilta-cel compared to ... ...

Abstract	Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy studied in patients with multiple myeloma exposed to three classes of treatment in the single-arm CARTITUDE-1 study. To assess the effectiveness of cilta-cel compared to real-world clinical practice (RWCP), we performed adjusted comparisons using individual patients' data from CARTITUDE-1 and LocoMMotion, a prospective, multinational study of patients with multiple myeloma triple-class exposed of treatment. Comparisons were performed using inverse probability weighting. In CARTITUDE-1, 113 patients were enrolled, and 97 patients were infused with cilta-cel. In LocoMMotion, 248 patients were enrolled, and 170 patients were included in the comparisons versus infused patients. Ninety-two unique regimens were used in LocoMMotion, most frequently carfilzomib-dexamethasone (13.7%), pomalidomide-cyclophosphamide-dexamethasone (13.3%) and pomalidomidedexamethasone (11.3%). Adjusted comparisons showed that patients treated with cilta-cel were 3.12-fold more likely to respond to treatment than those managed by RWCP (response rate, 3.12, 95% confidence interval [95% CI]: 2.24-4.00), had their risk of progression or death reduced to by 85% (progression-free survival hazard ratio=0.15, 95% CI: 0.08-0.29), and a risk of death lowered by 80% (overall survival hazard ratio HR=0.20, 95% CI: 0.09-0.41). The incremental improvement in healthrelated quality of life from baseline for cilta-cel versus RWCP at week 52, as measured by EORTC QLQ-C30 Global Health Status, was 13.4 (95% CI: 3.5-23.6) and increased to 30.8 (95% CI: 21.8-39.8) when including death as additional information regarding patients' health status. Patients treated with cilta-cel experienced more adverse events than those managed with RWCP (any grade: 100% vs. 83.5%). The results from this study demonstrate improved efficacy outcomes of cilta-cel versus RWCP and highlight its potential as a novel and effective treatment option for patients with multiple myeloma triple-class exposed of antimyeloma treatment. CARTITUDE-1 is registered with clinicaltrials gov. Identifier: NCT03548207. LocoMMotion is registered with clinicaltrials gov. Identifier: NCT04035226.
MeSH term(s)	Humans ; Multiple Myeloma/drug therapy ; Multiple Myeloma/etiology ; Proteasome Inhibitors/therapeutic use ; Immunomodulating Agents ; Prospective Studies ; Quality of Life ; Dexamethasone/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Chemical Substances	Proteasome Inhibitors ; Immunomodulating Agents ; Dexamethasone (7S5I7G3JQL)
Language	English
Publishing date	2023-08-01
Publishing country	Italy
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2022.280482
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis.

Freedman, M S / Duquette, P / Grand'Maison, F / Lee, L / Vorobeychik, G / Lara, N / Khurana, V / Nakhaipour, H R / Schecter, R / Haddad, P

Current medical research and opinion

2019 Volume 35, Issue 5, Page(s) 767–776

Abstract: Background: There is limited evidence on the effectiveness and healthcare costs of switching to fingolimod versus another first line injectable therapy (FLIT) in patients with relapsing multiple sclerosis (RMS) who have already been treated with FLIT.!## ...

Abstract	Background: There is limited evidence on the effectiveness and healthcare costs of switching to fingolimod versus another first line injectable therapy (FLIT) in patients with relapsing multiple sclerosis (RMS) who have already been treated with FLIT. Objective: The objectives of the study were to assess the annualized relapse rate (ARR), socio-demographic and clinical characteristics, persistence and adherence rates, healthcare resource utilization and cost among patients with RMS who either switch to fingolimod or another FLIT in routine clinical practice. Methods: A multicenter, observational, retrospective chart review was conducted across eight clinics in Canada between 1 May 2011 and 30 June 2013. The data was collected from two cohorts: patients who switched to fingolimod and patients who switched to FLIT from a previous FLIT. Results and conclusions: A total of 124 patients were included in the study: 82 and 42 switched to fingolimod and FLIT, respectively. There were no significant differences in the patient characteristics at the date of switch except for number of previous disease-modifying therapies (DMTs) which was higher in the fingolimod cohort (fingolimod: 1.52; FLIT: 1.10, p < .001). The ARR during the first year of switching was numerically higher in the FLIT cohort compared to the fingolimod cohort (FLIT: 0.9 [95% CI 0.3-1.6]; fingolimod: 0.3 [95% CI 0.1-0.5]). The negative binomial model adjusted for the number of previous DMTs confirmed a statistically significant difference in ARR between the fingolimod and FLIT cohorts at 12 months of follow-up (p = .012). In the fingolimod cohort, 20.7% of patients experienced at least one relapse compared to 38.1% in the FLIT cohort. In both groups, a high proportion of patients (>90%) showed good treatment adherence (≥80% of prescribed doses).
MeSH term(s)	Adult ; Female ; Fingolimod Hydrochloride/therapeutic use ; Health Care Costs ; Humans ; Immunosuppressive Agents/therapeutic use ; Injections ; Male ; Middle Aged ; Multiple Sclerosis/drug therapy ; Recurrence ; Retrospective Studies
Chemical Substances	Immunosuppressive Agents ; Fingolimod Hydrochloride (G926EC510T)
Language	English
Publishing date	2019-01-21
Publishing country	England
Document type	Comparative Study ; Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	80296-7
ISSN	1473-4877 ; 0300-7995
ISSN (online)	1473-4877
ISSN	0300-7995
DOI	10.1080/03007995.2019.1565818
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 955: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Supervised therapy in San Francisco.

Schecter, G F

Clinics in chest medicine

1997 Volume 18, Issue 1, Page(s) 165–168

Abstract: DOT is challenging, rewarding, and the best way we have of ensuring patients' adherence to treatment. Although labor intensive, the team approach with well-defined roles for the RN, DCI, and outreach worker is efficient and effective. Although the human ... ...

Abstract	DOT is challenging, rewarding, and the best way we have of ensuring patients' adherence to treatment. Although labor intensive, the team approach with well-defined roles for the RN, DCI, and outreach worker is efficient and effective. Although the human touch-a welcoming, tolerant, and caring approach to the patient-is the single key element, the use of incentives and enablers makes DOT more attractive to patients and the program more successful. An organized approach is necessary, yet flexibility must be maintained. Each patient has unique needs. Using other programs to help, such as school-based nurserun clinics or methadone sites, is more convenient for the patient and increases adherence. Helping patients access other services is important. And, finally, recognizing and appreciating the hard work and skills of the DOT staff contribute to maintaining high staff morale and esprit de corps.
MeSH term(s)	Communicable Disease Control ; Community Health Services ; Humans ; Medical Staff/psychology ; Morale ; Patient Care Team ; Patient Compliance ; San Francisco ; Tuberculosis/drug therapy ; Tuberculosis/prevention & control
Language	English
Publishing date	1997-03
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	447455-7
ISSN	1557-8216 ; 0272-5231
ISSN (online)	1557-8216
ISSN	0272-5231
DOI	10.1016/s0272-5231(05)70366-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 805: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evaluation of a change in cytomegalovirus prevention strategy following pediatric solid organ transplantation.

Pangonis, Scott / Paulsen, Grant / Andersen, Heidi / Flores, Francisco / Miethke, Alexander / Peters, Anna / Kocoshis, Samuel / Lazear, Danielle / Garr, BreAnn / Schecter, Marc / Chin, Clifford / Hemmelgarn, Trina / Danziger-Isakov, Lara

Transplant infectious disease : an official journal of the Transplantation Society

2019 Volume 22, Issue 2, Page(s) e13232

Abstract: Background: An optimal cytomegalovirus (CMV) prevention strategy following solid organ transplantation (SOT) remains uncertain. This study reports on the rates of CMV events following a change in a local prevention guideline involving increased ... ...

Abstract	Background: An optimal cytomegalovirus (CMV) prevention strategy following solid organ transplantation (SOT) remains uncertain. This study reports on the rates of CMV events following a change in a local prevention guideline involving increased surveillance, earlier transition to oral valganciclovir, and decreased CMV-immunoglobulin use. Methods: A retrospective cohort study utilizing historical controls evaluated the rates of CMV invasive disease pre- and post-intervention among pediatric heart, liver, and kidney recipients. Outcomes were recorded for the 4 years pre- and post-intervention, 9/2009-10/2017. Logistic regression was used to estimate the risk of a CMV event. Results: There was no difference in the rates of CMV invasive disease between the two study groups (P = 1). An increase in the detection of CMV events occurred (P = .04), predominantly asymptomatic CMV infection. This increase was independently associated with increased surveillance testing among high-risk heart and liver recipients, aOR 1.08 (1.06-1.12). Surprisingly, 28.9% of CMV events occurred during antiviral prophylaxis. Conclusions: Modification of the local CMV prevention guideline did not result in an increase in CMV invasive disease. CMV events occurred while on prophylaxis, highlighting a potential difference from adult solid organ transplant (SOT) and emphasizing the potential need for monitoring on prophylaxis in the pediatric population.
MeSH term(s)	Adolescent ; Antibodies, Viral/administration & dosage ; Antiviral Agents/administration & dosage ; Child ; Child, Preschool ; Cytomegalovirus ; Cytomegalovirus Infections/prevention & control ; Female ; Ganciclovir/administration & dosage ; Humans ; Immunoglobulins, Intravenous/administration & dosage ; Infant ; Logistic Models ; Male ; Organ Transplantation/adverse effects ; Primary Prevention/methods ; Retrospective Studies
Chemical Substances	Antibodies, Viral ; Antiviral Agents ; Immunoglobulins, Intravenous ; cytomegalovirus-specific hyperimmune globulin (129L90A25N) ; Ganciclovir (P9G3CKZ4P5)
Language	English
Publishing date	2019-12-30
Publishing country	Denmark
Document type	Journal Article ; Observational Study
ZDB-ID	1476094-0
ISSN	1399-3062 ; 1398-2273
ISSN (online)	1399-3062
ISSN	1398-2273
DOI	10.1111/tid.13232
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5100: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Developing an adolescent and adult Fontan Management Programme.

Lubert, Adam M / Alsaied, Tarek / Trout, Andrew T / Dillman, Jonathan R / Palermo, Joseph J / Eichelbrenner, Felicia / Kleier, Kelly / Lorts, Angela / Anwar, Nadeem / Schecter, Marc G / Tiao, Gregory M / Chin, Clifford / Feldman, David S / Jenkins, Meredith / Morales, David Ls / Opotowsky, Alexander R / Bucuvalas, John C / Veldtman, Gruschen R / Goldstein, Stuart L

Cardiology in the young

2021 Volume 32, Issue 2, Page(s) 230–235

Abstract: Patients with single-ventricle CHD undergo a series of palliative surgeries that culminate in the Fontan procedure. While the Fontan procedure allows most patients to survive to adulthood, the Fontan circulation can eventually lead to multiple cardiac ... ...

Abstract	Patients with single-ventricle CHD undergo a series of palliative surgeries that culminate in the Fontan procedure. While the Fontan procedure allows most patients to survive to adulthood, the Fontan circulation can eventually lead to multiple cardiac complications and multi-organ dysfunction. Care for adolescents and adults with a Fontan circulation has begun to transition from a primarily cardiac-focused model to care models, which are designed to monitor multiple organ systems, and using clues from this screening, identify patients who are at risk for adverse outcomes. The complexity of care required for these patients led our centre to develop a multidisciplinary Fontan Management Programme with the primary goals of earlier detection and treatment of complications through the development of a cohesive network of diverse medical subspecialists with Fontan expertise.
MeSH term(s)	Adolescent ; Adult ; Fontan Procedure/adverse effects ; Heart Defects, Congenital/surgery ; Humans ; Palliative Care ; Univentricular Heart
Language	English
Publishing date	2021-05-10
Publishing country	England
Document type	Journal Article
ZDB-ID	1078466-4
ISSN	1467-1107 ; 1047-9511
ISSN (online)	1467-1107
ISSN	1047-9511
DOI	10.1017/S104795112100175X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4050: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Costa, Luciano J / Hari, Parameswaran / Berdeja, Jesus G / De Stefano, Valerio / Gay, Francesca / Hooper, Becky / Bartlett, Meaghan / Haltner, Anja / Rosta, Emily / Kumar, Shaji / Martin, Thomas / Mateos, Maria-Victoria / Moreau, Philippe / Usmani, Saad Z / Olyslager, Yunsi / Schecter, Jordan M / Roccia, Tito / Garrett, Ashraf / Lee, Sam /

Nesheiwat, Tonia / Pacaud, Lida / Zhou, Changwei / Samjoo, Imtiaz A / Lin, Yi / Diels, Joris / Valluri, Satish / Weisel, Katja

Current medical research and opinion

2022 Volume 38, Issue 10, Page(s) 1759–1767

Abstract: Objective: ...

Abstract	Objective:
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Multiple Myeloma/drug therapy ; Physicians
Language	English
Publishing date	2022-08-10
Publishing country	England
Document type	Journal Article ; Meta-Analysis
ZDB-ID	80296-7
ISSN	1473-4877 ; 0300-7995
ISSN (online)	1473-4877
ISSN	0300-7995
DOI	10.1080/03007995.2022.2100651
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 955: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Linezolid in the treatment of multidrug-resistant tuberculosis.

Schecter, G F / Scott, C / True, L / Raftery, A / Flood, J / Mase, S

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

2010 Volume 50, Issue 1, Page(s) 49–55

Abstract: Background: Linezolid is a new antibiotic with activity against Mycobacterium tuberculosis in vitro and in animal studies. Several small case series suggest that linezolid is poorly tolerated because of the side effects of anemia/thrombocytopenia and ... ...

Abstract	Background: Linezolid is a new antibiotic with activity against Mycobacterium tuberculosis in vitro and in animal studies. Several small case series suggest that linezolid is poorly tolerated because of the side effects of anemia/thrombocytopenia and peripheral neuropathy. To characterize our clinical experience with linezolid, the California Department of Public Health Tuberculosis Control Branch's Multidrug-Resistant Tuberculosis (MDR-TB) Service reviewed cases in which the MDR-TB treatment regimens included linezolid therapy. Methods: Record review was performed for 30 patients treated with linezolid as part of an MDR-TB regimen. Data were collected on clinical and microbiological characteristics, linezolid tolerability, and treatment outcomes. The dosage of linezolid was 600 mg daily. Vitamin B6 at a dosage of 50-100 mg daily was used to mitigate hematologic toxicity. Results: During 2003-2007, 30 patients received linezolid for the treatment of MDR-TB. Patients had isolates resistant to a median of 5 drugs (range, 2-13 drugs). Of the 30 cases, 29 (97%) were pulmonary; of these 29, 21 (72%) had positive results of acid-fast bacilli smear, and 16 (55%) were cavitary. Culture conversion occurred in all pulmonary cases at a median of 7 weeks. At data censure (31 December 2008), 22 (73%) of 30 patients had successfully completed treatment. Five continued to receive treatment. There were no deaths. Three patients had a poor outcome, including 2 defaults and 1 treatment failure. Side effects occurred in 9 patients, including peripheral and optic neuropathy, anemia/thrombocytopenia, rash, and diarrhea. However, only 3 patients stopped linezolid treatment because of side effects. Conclusions: Linezolid was well tolerated, had low rates of discontinuation, and may have efficacy in the treatment of MDR-TB.
MeSH term(s)	Acetamides/adverse effects ; Acetamides/therapeutic use ; Adolescent ; Adult ; Aged ; Antitubercular Agents/adverse effects ; Antitubercular Agents/therapeutic use ; Female ; Humans ; Linezolid ; Male ; Middle Aged ; Mycobacterium tuberculosis/drug effects ; Oxazolidinones/adverse effects ; Oxazolidinones/therapeutic use ; Retrospective Studies ; Treatment Outcome ; Tuberculosis, Multidrug-Resistant/drug therapy ; Tuberculosis, Multidrug-Resistant/microbiology
Chemical Substances	Acetamides ; Antitubercular Agents ; Oxazolidinones ; Linezolid (ISQ9I6J12J)
Language	English
Publishing date	2010-01-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	1099781-7
ISSN	1537-6591 ; 1058-4838
ISSN (online)	1537-6591
ISSN	1058-4838
DOI	10.1086/648675
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1505: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 480: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Plesner, Torben / Arkenau, Hendrik-Tobias / Gay, Francesca / Minnema, Monique C / Boccadoro, Mario / Moreau, Philippe / Cavenagh, Jamie / Perrot, Aurore / Laubach, Jacob P / Krejcik, Jakub / Ahmadi, Tahamtan / de Boer, Carla / Chen, Diana / Chiu, Christopher / Schecter, Jordan M / Richardson, Paul G

British journal of haematology

2019 Volume 186, Issue 3, Page(s) e35–e39

MeSH term(s)	Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Female ; Humans ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Male ; Multiple Myeloma/drug therapy ; Neoplasm Recurrence, Local ; Progression-Free Survival
Chemical Substances	Angiogenesis Inhibitors ; Antibodies, Monoclonal ; daratumumab (4Z63YK6E0E) ; Dexamethasone (7S5I7G3JQL) ; Lenalidomide (F0P408N6V4)
Language	English
Publishing date	2019-03-31
Publishing country	England
Document type	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.15879
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito